نتایج جستجو برای: vi mps

تعداد نتایج: 47894  

Journal: :Molecular genetics and metabolism 2015
Yew Sing Choy Kaustuv Bhattacharya Shanti Balasubramaniam Michael Fietz Antony Fu Anita Inwood Dong-Kyu Jin Ok-Hwa Kim Motomichi Kosuga Young Hee Kwun Hsiang-Yu Lin Shuan-Pei Lin Nancy J Mendelsohn Torayuki Okuyama Hasri Samion Adeline Tan Akemi Tanaka Verasak Thamkunanon Meow-Keong Thong Teck-Hock Toh Albert D Yang Jim McGill

Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) is caused by deficient activity of the enzyme, N-acetylgalactosamine-4-sulfatase, resulting in impaired degradation of the glycosaminoglycan dermatan sulfate. Patients experience a range of manifestations including joint contractures, short stature, dysostosis multiplex, coarse facial features, decreased pulmonary function, cardiac abno...

2009
Regina P El Dib Gregory M Pastores

INTRODUCTION Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) is an autosomal recessive lysosomal storage disorder, characterized primarily by skeletal dysplasia and joint contracture. It is caused by a deficiency of N-acetylgalactosamine-4-sulfatase (arylsulfatase B), for which a recombinant formulation (galsulfase) is available as replacement therapy. OBJECTIVE To evaluate th...

Journal: :AJNR. American journal of neuroradiology 1989
R Murata S Nakajima A Tanaka N Miyagi O Matsuoka S Kogame Y Inoue

MR imaging of the brain was performed in eight patients with mucopolysaccharidosis (MPS). Two had MPS I S, one had MPS IIA, two had MPS IIB, two had MPS IIIB, and one had MPS VI. In the patients with MPS IIA and MPS VI, T1 and T2 were prolonged in various areas of the cerebral white matter. These findings seemed to correspond with the development of pathologic changes in MPS, such as perivascul...

2015
Rita Ferla Pamela Claudiani Marco Savarese Karen Kozarsky Rossella Parini Maurizio Scarpa Maria Alice Donati Giovanni Sorge John J. Hopwood Giancarlo Parenti Simona Fecarotta Vincenzo Nigro Hatice Serap Sivri Ans Van Der Ploeg Generoso Andria Nicola Brunetti-Pierri Alberto Auricchio

Recombinant vectors based on adeno-associated virus serotype 8 (AAV8) have been successfully used in the clinic and hold great promise for liver-directed gene therapy. Preexisting immunity against AAV8 or the development of antibodies against the therapeutic transgene product might negatively affect the outcomes of gene therapy. In the prospect of an AAV8-mediated, liver-directed gene therapy c...

2012
Bruno Duarte Gomes Givago da Silva Souza Gustavo Monteiro Viana Isabel Cristina Neves de Souza Patricia do Socorro Queiroz Feio Ida Vanessa Doederlein Schwartz Diane Ruschel Marinho Manoel da Silva Filho Roberto Giugliani Luiz Carlos de Lima Silveira Luiz Carlos Santana da Silva

PURPOSE To evaluate the visual system of patients suffering from type I or VI mucopolysaccharidosis (MPS) by recording the visual evoked cortical potential (VECP). METHODS Two patients with MPS VI and 2 patients with MPS I were tested before and after enzyme replacement therapy (ERT). A control group of 20 subjects was tested for statistical comparison. VECP was elicited by monocular stimulat...

Journal: :Molecular genetics and metabolism 2011
Dafne Dain Gandelman Horovitz Tatiana de Sá Pacheco Carneiro Magalhães Alessandra Pena e Costa Luis Eduardo Carelli Daniel Souza e Silva Anna Patricia Freitas de Linhares e Riello Juan Clinton Llerena

Spinal cord compression (SCC) is a known complication of mucopolysaccharidosis type VI (MPS VI) secondary to atlantoaxial subluxation, craniovertebral stenosis, posterior longitudinal ligament hypertrophy, or dural thickening. SCC is expected to occur in the natural history of the disease, regardless of enzyme replacement therapy (ERT), as intravenous enzyme does not cross the blood-brain barri...

Journal: :Human heredity 2014
Fabiana Moura Costa-Motta Fernanda Bender Angelina Acosta Kiyoko Abé-Sandes Taísa Machado Thaís Bomfim Tatiana Boa Sorte Danniel da Silva Alan Bittles Roberto Giugliani Sandra Leistner-Segal

Mucopolysaccharidosis type VI (MPS VI - Maroteaux-Lamy syndrome) is a globally rare lysosomal storage disease caused by a deficiency of arylsulfatase B. However, in Monte Santo, a poor and isolated rural region in Northeast Brazil with large family sizes and high rates of community endogamy and parental consanguinity (α = 0.00483), 9 living and 4 now deceased individuals in 11 kindreds have bee...

Journal: :Journal of pediatric rehabilitation medicine 2010
Arline McDonald Robert Steiner Kerry Kuehl Sean Turbeville

Increased functional capacity of major organ systems improves the quality of life and contributes to reductions in the morbidity associated with chronic debilitating diseases. Routine endurance tests can be used to gauge the progression of disease and the impact of therapeutic modalities in disorders with multiple organ system involvement such as with Mucopolysaccharidosis type VI (MPS VI). MPS...

Journal: :The Journal of clinical investigation 1996
A C Crawley D A Brooks V J Muller B A Petersen E L Isaac J Bielicki B M King C D Boulter A J Moore N L Fazzalari D S Anson S Byers J J Hopwood

We report studies that suggest enzyme replacement therapy will result in a significant reduction in disease progression and tissue pathology in patients with Maroteaux-Lamy syndrome (Mucopolysaccharidosis type VI, MPS VI). A feline model for MPS VI was used to evaluate tissue distribution and clinical efficacy of three forms of recombinant human N-acetylgalactosamine-4-sulfatase (rh4S, EC 3.1.6...

2011
V Opoka – Winiarska A Jurecka A Tylki – Szymańska A Emeryk

Background Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) is an autosomal recessive lysosomal storage disorder determined by mutations in the arylsulfatase B gene located in chromosome 5. Pathogenic mutations of this gene result in reduced or absent activity of enzyme arylsulfatase B (N-acetylgalactosamine 4-sulfatase, ARSB). Incomplete degradation and cellular accumulation of glyco...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید